Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 116.43B +34.8% |
| Revenue (ttm) | 25.29B +20.7% |
| Net Income | 5.32B -27.7% |
| EPS | 84.98 -25.8% |
| Shares Out | 61.39M |
| PE Ratio | 22.32 |
| Forward PE | 22.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1,894.50 |
| Previous Close | 1,896.50 |
| Day's Range | 1,868.00 - 1,902.50 |
| 52-Week Range | 1,308.00 - 2,257.00 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 2,313.13 (+22.26%) |
| Earnings Date | Aug 6, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price target is kr 2,313, which is an increase of 22.26% from the latest price.
News
Genmab says EC grants marketing authorization for Tepkinly combo
Genmab (GMAB) announced that the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or re...
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenali...
Genmab price target raised to $40 from $38 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Genmab (GMAB) to $40 from $38 and keeps a Buy rating on the shares after the company announced that…
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
Genmab (GMAB) Reports Positive Phase 3 Trial Results for Epcoritamab
Genmab (GMAB) Reports Positive Phase 3 Trial Results for Epcoritamab
Genmab announces topline results from EPCORE DLBCL-4 trial
Genmab (GMAB) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneousl...
Genmab reports ‘positive’ Phase 3 results from EPCORE DLBCL-4 trial
Genmab (GMAB) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneousl...
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets ...
Genmab (GMAB) Reports Promising Results for Epcoritamab in DLBCL Studies
Genmab (GMAB) Reports Promising Results for Epcoritamab in DLBCL Studies
Genmab announces new data from studies evaluating epcoritamab
Genmab (GMAB) announced new data from two studies evaluating epcoritamab. Results from the Phase 2 EPCORE DLBCL-3 study showed an overall response rate, ORR, of 67% and a complete response…
Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients
(RTTNews) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not eli...
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-l...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to em...
Genmab (GMAB) Reports Strong Data from EPCORE FL-1 Trial Analysis
Genmab (GMAB) Reports Strong Data from EPCORE FL-1 Trial Analysis
Genmab Reports Epcoritamab Benefits Across Relapsed Follicular Lymphoma Subgroups
(RTTNews) - Genmab A/S (GMAB) on Thursday presented new subgroup data from the Phase 3 EPCORE FL-1 trial showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivered consiste...
Genmab presents EPCORE FL-1 subgroup data at EHA 2026 Congress
Genmab (GMAB) announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in combinatio...
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE® FL-1 trial, evaluating epcoritamab, a subcut...
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
Genmab assumed with a Buy at Truist
Truist analyst Gregory Renza assumed coverage of Genmab (GMAB) with a Buy rating and a price target of $40, down from $48. The firm is positive on the company’s transition…
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab...
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,400 and keeps a Buy rating on the shares. Published first on…
Genmab announces 5.08% stake by Orbis Investment
Genmab (GMAB) announces that Orbis Investment Management has informed the company that through shares, as of May 8, it controlled the voting rights to 3,166,357 shares in Genmab, which amounts…
Genmab price target lowered to $33 from $34 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Genmab (GMAB) to $33 from $34 and keeps an Equal Weight rating on the shares.